| Assessment Status | Full HTA Assessment |
| HTA ID | - |
| Drug | Rivaroxaban |
| Brand | Xarelto® |
| Indication | For the Primary Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Total Hip Replacement or Total Knee Replacement. |
| Assessment Process | |
| Full submission received from Applicant | 01/05/2008 |
| NCPE assessment completed | 18/09/2008 |
| NCPE assessment outcome | Reimbursement Recommended |
A summary of the main findings are included in the attached document.